I-2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid

I-2'-Methoxy-3'-nitro-biphenyl-3-carboxylic acid isetyenziswe njengendawo ephakathi kwe-Eltrombopag.
I-Eltrombopag, ephuhliswe yi-GlaxoSmithKline (GSK) e-UK kwaye kamva iphuhliswe ngokudibeneyo kunye ne-Novartis eSwitzerland, yeyokuqala kwaye ivunyiwe kuphela i-molecule encinci ye-non peptide TPO receptor agonist emhlabeni.I-Eltrombopag yavunywa yi-US FDA kwi-2008 yonyango lwe-idiopathic thrombocytopenic purpura (ITP), kunye ne-2014 yonyango lwe-anemia ye-aplastic enzima (AA).Ikwalichiza lokuqala elavunywa yi-US FDA kunyango lwe-AA kwiminyaka engama-30 yakutsha nje.
NgoDisemba 2012, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kwizigulane ezine-hepatitis C engapheliyo (CHC), ukwenzela ukuba izigulane ze-hepatitis C ezine-prognosis embi ngenxa yokubala kweplatelet ephantsi inokuqala kwaye igcine unyango oluqhelekileyo lwe-interferon kwizifo zesibindi.NgoFebruwari3, 2014, i-GlaxoSmithKline yabhengeza ukuba i-FDA inike isiqinisekiso sonyango lwe-Eltrombopag kunyango lwe-hemopenia kwizigulane ezine-chemicalbook aplastic anemia (SAA) ezinzima ezingazange ziphendule ngokupheleleyo kwi-immunotherapy.Ngo-Agasti 24, i-2015, i-US FDA ivume i-Eltrombopag yonyango lwe-thrombocytopenia kubantu abadala kunye nabantwana abaneminyaka eyi-1 kunye nangaphezulu kunye ne-immune immune thrombocytopenia (ITP) abangenayo impendulo eyaneleyo kwi-corticosteroids, i-immunoglobulins okanye i-splenectomy.NgoJanuwari4, 2018, i-Eltrombopag yavunywa ukuba ibhalwe e-China kunyango lwe-immune immune thrombocytopenia (ITP).